Dietary and nutraceutical approach to type 2 diabetes

Archives of Medical Science

Volumn 10, Issue 2, 2014, Pages 336-344

  Derosa, Giuseppe ^a,b   Limas, Celina Preciado ^c   Maciás, Pilar Ceballos ^c   Estrella, Aceves ^c   Maffioli, Pamela ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

Author keywords

Berberine; Diabetes; Diet; L carnitine; 3

Indexed keywords

BERBERINE; CARBOHYDRATE; CARNITINE; FAT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PROTEIN; SWEETENING AGENT; THIOCTIC ACID;

CARBOHYDRATE INTAKE; DIABETIC PATIENT; DIET SUPPLEMENTATION; DIET THERAPY; FAT INTAKE; FIBER; FOOD COMPOSITION; FOOD INTAKE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN INTAKE; REVIEW;

EID: 84901033332     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.42587     Document Type: Review

References (47)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31. (Pubitemid 28405191)
2. Bissinger A, Grycewicz T, Grabowicz W, Lubinski A. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci 2011; 7: 806-12.
3. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond) 2006; 110: 143-52. (Pubitemid 43241476)
4. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7. (Pubitemid 46024995)
5. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009; 116: 507-12.
6. Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008; 40: 442-5.
7. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460-6. (Pubitemid 37444406)
8. Ueno K, Anzai T, Jinzaki M, et al. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlusive lesions. Circ J 2009; 73: 1927-33.
9. Ješić M, Sajić S, Ješić M, et al. Microalbuminuria in relation to metabolic control and blood pressure in adolescents with type 1 diabetes. Arch Med Sci 2011; 7: 1037-41.
10. Konishi M, Sugiyama S, Sugamura K, et al. Association of pericardial fat accumulation rather than abdominal obesity with coronary atherosclerotic plaque formation in patients with suspected coronary artery disease. Atherosclerosis 2010; 209: 573-8.
11. Athyros VG, Hatzitolios AI, Karagiannis A, et al.; IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
12. Reyes Ramírez MP, Morales González JA, Madrigal Santillán EO. Diabetes. Tratamiento nutricional. Med Int Mex 2009; 25: 454-60.
13. American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 (Suppl. 1): S61-78.
14. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Nutrition Therapy. Can J Diabetes 2008; 32 (Suppl. 1): S40-5.
15. Franz MJ, Boucher JL, Green-Pastors J, Powers MA. Evidence-based nutrition practice guidelines for diabetes and scope and standards of practice. J Am Diet Assoc 2008; 108 (4 Suppl. 1): S52-8. (Pubitemid 351389299)
16. Lerman I, López-Ponce A, Villa AR, et al. Pilot study of two different strategies to reinforce self care behaviors and treatment compliance among type 2 diabetes patients from low income strata. Gac Med Mex 2009; 145: 15-9.
17. Mann JI, De Leeuw I, Hermansen K, et al.; Diabetes and Nutrition Study Group (DNSG) of the European Association. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004; 14: 373-94. (Pubitemid 40459260)
18. Koura HM, Abdallah Ismail N, Kamel AF, Ahmed AM, Saad-Hussein A, Effat LK. A long-term study of bone mineral density in patients with phenylketonuria under diet therapy. Arch Med Sci 2011; 7: 493-500.
19. Yamada Y, Hosoya S, Nishimura S, et al. Effect of bread containing resistant starch on postprandial blood glucose levels in humans. Biosci Biotechnol Biochem 2005; 69: 559-66. (Pubitemid 40589116)
20. Higgins JA. Resistant starch: metabolic effects and potential health benefits. J AOAC Int 2004; 87: 761-8.
21. Liu J, Shen W, Zhao B, et al. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv Drug Deliv Rev 2009; 61: 1343-52.
22. Rajasekar P, Anuradha CV. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. Exp Diabetes Res 2007; 2007: 72741.
23. Calò LA, Pagnin E, Davis PA, et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107: 54-60. (Pubitemid 41767518)
24. Dayanandan A, Kumar P, Panneerselvam C. Protective role of L-carnitine on liver and heart lipid peroxidation in atherosclerotic rats. J Nutr Biochem 2001; 12: 254-7. (Pubitemid 32520838)
25. Lee MS, Lee HJ, Lee HS, Kim Y. L-carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med Food 2006; 9: 468-73. (Pubitemid 46095353)
26. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1429-39. (Pubitemid 36677286)
27. Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis. A randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338-45.
28. Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension 2009; 54: 462-4.
29. Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol 2011; 25: 642-51.
30. Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010; 57: 777-86.
31. Derosa G, Maffioli P, Salvadeo SA, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010; 49: 1717-25.
32. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011; 60: 421-9.
33. Booker SJ. Unraveling the pathway of lipoic acid biosynthesis. Chem Biol 2004; 11: 10-2. (Pubitemid 38203982)
34. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis 2004; 14: 351-7. (Pubitemid 40459257)
35. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004; 10: 727-33. (Pubitemid 38937638)
36. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 712-7. (Pubitemid 351608234)
37. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010; 59: 285-92.
38. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012; 4: 77-83.
39. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008; 93: 2559-65. (Pubitemid 352008520)
40. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012; 12: 1113-24.
41. Marchioli R, Barzi F, Bomba E, et al.; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903. (Pubitemid 34437615)
42. Gissi-HF Investigators; Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-30.
43. Derosa G, Maffioli P, D'Angelo A, et al. Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opin Pharmacother 2009; 10: 1239-47.
44. Lewandowski KC, Banach E, Bieńkiewicz M, Lewiński A. Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci 2011; 7: 294-303.
45. Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bonaventura A, Maffioli P. Effects of n-3 PUFAs on insulin resistance after an oral fat load. Eur J Lipid Sci Technol 2011; 113: 950-60.
46. Derosa G, Cicero AFG, Fogari E, et al. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012; 6: 553-64.
47. Cicero AF, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C. Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 2010; 32: 137-44.